Free Trial
NASDAQ:OPGN

OpGen (OPGN) Stock Price, News & Analysis

OpGen logo
$3.97 +0.57 (+16.78%)
As of 03:59 PM Eastern

About OpGen Stock (NASDAQ:OPGN)

Key Stats

Today's Range
$2.96
$4.00
50-Day Range
$0.69
$3.97
52-Week Range
$0.53
$8.40
Volume
23,456 shs
Average Volume
6,676 shs
Market Capitalization
$33.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

Remove Ads
Receive OPGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter.

OPGN Stock News Headlines

OpGen (NASDAQ:OPGN) Coverage Initiated at StockNews.com
New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
OpGen Appoints New COO and Company Secretary
OPGN Stock Earnings: OpGen Reported Results for Q2 2024
See More Headlines

OPGN Stock Analysis - Frequently Asked Questions

OpGen's stock was trading at $0.5950 at the beginning of the year. Since then, OPGN shares have increased by 567.2% and is now trading at $3.97.
View the best growth stocks for 2025 here
.

OpGen, Inc. (NASDAQ:OPGN) posted its quarterly earnings data on Thursday, August, 10th. The medical research company reported ($9.30) EPS for the quarter, missing analysts' consensus estimates of ($7.10) by $2.20. The medical research company earned $0.74 million during the quarter, compared to analyst estimates of $0.90 million.

OpGen's stock reverse split on Monday, May 20th 2024. The 1-10 reverse split was announced on Monday, May 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

OpGen (OPGN) raised $17 million in an initial public offering (IPO) on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that OpGen investors own include NVIDIA (NVDA), Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Broadcom (AVGO).

Company Calendar

Last Earnings
8/10/2023
Today
3/28/2025
Next Earnings (Estimated)
6/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NASDAQ:OPGN
Employees
100
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-32,670,000.00
Net Margins
-1,140.36%
Pretax Margin
-742.42%

Debt

Sales & Book Value

Annual Sales
$2.67 million
Price / Cash Flow
N/A
Book Value
($11.55) per share
Price / Book
-0.35

Miscellaneous

Free Float
4,696,000
Market Cap
$33.34 million
Optionable
Not Optionable
Beta
0.34

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:OPGN) was last updated on 3/28/2025 by MarketBeat.com Staff
From Our Partners